L-tyrosine ( DrugBank: Tyrosine, L-tyrosine )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 1 |
| 111 | Congenital myopathy | 1 |
6. Parkinson disease
Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02259049 (ClinicalTrials.gov) | October 2014 | 3/10/2014 | The Effects of L-Tyrosine on 24 Hour Blood Pressure and Heart Rate in Parkinson's Disease | The Effects of L-Tyrosine on Non-invasive Ambulatory Blood Pressure and Heart Rate Monitoring in Parkinson's Disease | Blood Pressure | Dietary Supplement: L-tyrosine;Dietary Supplement: Sugar Pill | New York Institute of Technology | NULL | Completed | 40 Years | 84 Years | Both | 6 | Phase 0 | United States |
111. Congenital myopathy
Clinical trials : 11 / Drugs : 17 - (DrugBank : 5) / Drug target gene : 1 - Drug target pathways : 9
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02035501 (ClinicalTrials.gov) | January 2014 | 2/7/2013 | Treatment of TNNT1-Myopathy With L-Tyrosine. | Treatment of TNNT1-Myopathy With L-Tyrosine. A Double-blind, Placebo-controlled Crossover Trial. | Nemaline Myopathy | Drug: L-Tyrosine;Drug: Placebo | Hadassah Medical Organization | NULL | Enrolling by invitation | N/A | 20 Years | Both | 10 | Phase 2 | Israel |